At a glance
| Development code | ZP8396 |
|---|---|
| Target family | Amylin-related receptors |
| Studied route | Subcutaneous injection |
| Phase 2 program | ZUPREME |
| Status | Investigational |
Overview
Formerly ZP8396, petrelintide is being developed by Zealand Pharma and Roche as a long-acting amylin-based obesity treatment. The ZUPREME-1 study evaluated adults without type 2 diabetes over forty-two weeks, while other studies address diabetes and potential combinations. The program is clinically substantive, but a phase 2 result does not establish the full benefit-risk profile or imply that every amylin analog behaves alike. In particular, petrelintide, cagrilintide and pramlintide differ in molecule, duration, formulation and approved or investigational purpose, so their evidence should not be pooled into one product claim.
How it works
Amylin is a pancreatic peptide involved in satiation and meal-related regulation. Petrelintide is engineered to extend amylin-related receptor signaling and reduce food intake with prolonged exposure. This mechanism offers a route to appetite regulation that does not require GLP-1 agonism in the same molecule. Clinical trials are needed to determine whether the design produces a useful balance of weight reduction and tolerability.
Development population
ZUPREME-1 enrolled adults with obesity or qualifying overweight without type 2 diabetes. Separate development addresses adults with diabetes and combinations. These populations should remain distinct when presenting expected outcomes.
Phase 2 weight results
The study randomized 493 participants, with 485 exposed to treatment. Mean weight reduction continued through forty-two weeks, reaching up to 10.7% in the reported efficacy analysis. The analysis assumed a particular treatment-adherence scenario rather than predicting every real-world outcome.
Supporting sources [1]
What favorable tolerability means
Nausea was more frequent with petrelintide than placebo; vomiting was uncommon, and diarrhea and constipation rates were relatively similar. This is an encouraging study-specific pattern, not evidence of no gastrointestinal effects or proof of superiority to another agent.
Supporting sources [1]
Questions phase 2 cannot settle
The trial was not designed to establish reductions in cardiovascular events or mortality. Longer-term persistence, uncommon harms and effects in more diverse populations remain relevant, even when average weight reduction and short-term tolerability look favorable.
Supporting sources [1]
Next-stage interpretation
Roche and Zealand describe continued development, including plans for later-stage studies and combinations. Company announcements are useful for program status but should be identified separately from peer-reviewed clinical findings and final regulatory decisions.
Reading this profile
Jurisdiction: Investigational; no FDA-approved petrelintide medicine identified as of 2026-10-27.. Molecular class: Long-acting human amylin analog peptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. ↗Original research · Checked 2026-10-27
- Roche: Petrelintide ZUPREME-1 phase 2 results, March 2026 ↗Manufacturer / sponsor · Checked 2026-10-27
- Zealand Pharma: Petrelintide pipeline ↗Manufacturer / sponsor · Checked 2026-10-27
- ClinicalTrials.gov: A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity ↗Clinical trial source · Checked 2026-10-27